TheraCell’s TheraFuse™ Oxygenation technology utilizes perfluorocarbons, which have been investigated for many years as blood substitutes due to their high oxygen capacity, and are currently used in a number of medical products in the USA. Their use as a component of an orthopedic implant is novel and TheraCell was granted a US patent in October 2014. The technology allows healing to be effected even before the body has developed vascularization of a site, and thus acts as a powerful stimulus to the healing process. The use of Theracell’s proprietary oxygenation technology provides a cost effective alternative to the use of the more expensive morphogenic protein products that have recently become less popular due to safety concerns. In-vivo proof of concept has been demonstrated in rat subcutaneous and intramuscular models and the technology is now being further developed in conjunction with our DBF™ Fiber Matrix Technology™
TheraCell has technology allowing the selection of stem cells at the point of care using a microfluidic cell sorting device.